Sign in to continue:

Tuesday, February 10th, 2026

Karex Seeks Rebound with Promising Technical Setup

Date: October 21, 2024
Broker: CGS International Securities Malaysia Sdn. Bhd.

Company Overview

Karex is a leading manufacturer of condoms and other rubber products, supplying both consumer and commercial markets. It is recognized as one of the largest condom manufacturers in the world, catering to various brands and organizations globally.

Recent Stock Performance

  • Last Price: RM 0.835
  • Karex’s stock has been trading slightly below its initial entry price, reflecting a period of consolidation. However, the technical indicators suggest potential for a rebound, making it a stock to watch in the short term.

Technical Analysis

  • Entry Price: RM 0.865
  • Current Price: RM 0.835
  • Stop Loss: RM 0.775
  • Target Prices: RM 0.895, RM 0.96

Trading Position

  • Current Position: Buy
  • Weighting in Portfolio: 8%
  • Shares Held: 115,600
  • Total Cost: RM 99,994.00
  • Market Value: RM 96,526.00
  • Profit/Loss: -RM 3,468.00 (-3.5%)

Trading Recommendation

The stock is currently held in a “Buy” position despite experiencing a minor loss. The stop-loss level is set at RM 0.775 to manage risks effectively. The technical setup suggests that there is still potential for a recovery, with upside targets of RM 0.895 and RM 0.96. Traders are advised to monitor the price action closely and adjust positions as needed.

Conclusion

Karex remains in the actively managed portfolio with the expectation of a possible rebound. While the stock has faced some downward pressure, technical analysis indicates the possibility of gains if the stock can surpass its current resistance levels. Investors are encouraged to keep an eye on the stock’s movements and adhere to the stop-loss for risk management.

Is This the Next Big Thing in Pharma? Hansoh’s Growth Story You Can’t Ignore!

Hansoh Pharma (3692 HK) Investing in Hansoh Pharmaceutical Group Co. Ltd. (3692 HK) presents a compelling opportunity based on several key factors: 1. Robust Financial Performance: Hansoh Pharma has demonstrated strong revenue and earnings...

Singapore Stock Market Report: Singtel Analysis, Geo Energy Update & Fund Flow Trends (May 2025)

Lim & Tan Securities Pte Ltd 22 May 2025 Daily Market Review and Key Investment Ideas Financial Market Overview The FSSTI Index closed at 3,882.6, showing no change (0.0%) for the day, a 1.3%...

DBS Leads Singapore Banks in Capital Returns as UOB Optimizes Structure, OCBC Lags in Buybacks

DBS Outshines Rivals with Balanced Capital Return Plan, UOB Boasts Most Optimized Structure DBS Group Holdings’ capital return strategy has been hailed as the most balanced and effective among Singapore’s top three banks, according...